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ABSTRACT
On issues of 35 U.S.C. §112, the Federal Circuit has been inconsistent in determining the extent to
which patent applicants need to disclose examples of their claimed inventions in patent
specifications to fully enable their patent claims. Confusion as to how many or what types of
examples amount to sufficient disclosure is augmented for inventions in the unpredictable arts, such
as chemistry, biotechnology, and pharmaceuticals. Current practice skewing towards disclosure of
examples in greater numbers is a misguided effort to satisfy enablement, as shown by patents at
issue in two recent Federal Circuit cases. A qualitative approach to disclosure is recommended, and
post filing experimental data is proposed as a limited remedy to retroactively fill gaps in disclosure
during patent prosecution.
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BRIDGE THE GAP IN PATENT DISCLOSURE OF NON-ENABLING
SPECIFICATIONS IN THE UNPREDICTABLE ARTS?
FEI SHA*
I. INTRODUCTION
What do you do when enough is not enough? For instance, inventors are
informed by the United States Patent and Trademark Office (“USPTO”) or a federal
court that not enough examples of their invention are disclosed in their patent
application to support the patent claims.1 What can they do to remedy the
insufficiency?2 What if numerous examples are already disclosed in the patent
specification?3 When forty-one examples of a therapeutic antibody may still be
deemed insufficient, what more can be done?4 What is needed to overcome such a
ruling or objection from the USPTO and federal courts? One must turn to 35 U.S.C.
§112(a) in order to begin to answer this question.5
Defining patent enablement, 35 U.S.C. §112(a) ambiguously provides that
disclosure of an invention in the specification of a patent or patent application is
adequate when it enables a person having ordinary skill in the art (“PHOSITA”) to
practice the claimed invention.6 Moreover, the specification must disclose an optimal
way of practicing the claimed invention, as contemplated by the inventor.7 At the
same time, U.S. patent law does not require the specification to describe how to make
and use every possible variant of a claimed invention.8 Rather, people with ordinary
* © Fei Sha 2019. Juris Doctor Candidate, May 2020, The John Marshall Law School; B.A. in
Biological Sciences, The University of Chicago (2007).
1 In re Vaeck, 947 F.2d 488, 490, 492–93, 495 (Fed. Cir. 1991) (A claimed invention
encompassing a chimeric hybrid DNA derived from bacteria and capable of being expressed in one
hundred fifty different genera of cyanobacteria was found not enabled in view of a specification
disclosing expression of the hybrid DNA in only one particular species of cyanobacteria illustrated in
nine examples.); see also U.S. Patent No. 5,516,693 cols. 5–14.
2 See id. (Given that heterologous gene expression in cyanobacteria was unpredictable at the
time of filing of the subject patent, additional working examples beyond the nine examples disclosed
that illustrate the heterologous gene expression in additional species of cyanobacteria could have
sufficiently enabled the patent specification.).
3 U.S. Patent No. 8,829,165 (Filed as a continuation of parent U.S. Patent No. 8,030,457, it
disclosed forty-one examples of the subject invention in the patent specification.).
4 See Amgen v. Sanofi, 872 F.3d 1367, 1372–76, 1378–79 (Fed. Cir. 2017).
5 35 U.S.C. §112(a). The specification shall contain a written description of the invention, and
of the manner and process of making and using it, in such full, clear, concise, and exact terms as to
enable any person skilled in the art to which it pertains, or with which it is most nearly connected,
to make and use the same, and shall set forth the best mode contemplated by the inventor or joint
inventor of carrying out the invention.
6 See id.
7 See id.
8 AK Steel v. Sollac, 344 F.3d 1234, 1244 (Fed. Cir. 2003) (“That is not to say that the
specification itself must necessarily describe how to make and use every possible variant of the
claimed invention, for the artisan’s knowledge of the prior art and routine experimentation can often
fill gaps, interpolate between embodiments, and perhaps even extrapolate beyond the disclosed
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skill in the art that seek to practice the invention should be able to fill any gaps in
the disclosure of the invention with their own knowledge, with proof of existing
background art and routine experimentation.9 PHOSITAs are expected to be able to
extrapolate beyond the disclosed examples, or embodiments, in their practice of the
invention.10 So, how can patent applicants draft the specification so as to meet the
PHOSITA halfway, so to speak, without giving away the tricks used to develop the
invention?
The standard of enablement has evolved over the past few decades.11 Most
notably, following the boom in the chemical, biotechnological, and pharmaceutical
industries, the enablement requirement was heightened such that disclosure of a
single embodiment was no longer sufficient to demonstrate the full scope of a
patent.12 For example, certain types of inventions in biotechnology have an even
stricter standard for enablement.13
Post filing data is a possible remedy that patent applicants can rely on to fill in
any identifiable gaps in the initial disclosure.14 Although limited, post filing
experimental data can be filed to supplement the specification by demonstrating an
enabling disclosure of the invention.15 Therefore, certain post filing data can be used
to enable claims in the unpredictable arts, including biotechnology.16 However, this
must be done with caution and used in appropriate circumstances, which will be
discussed below.
First, the evolution of the standard governing enablement will be examined.
Once that is clearly established, two recent notable examples of patents disclosing
large numbers of embodiments of the claimed inventions will be analyzed in detail
with respect to enablement of the patent specification. Finally, a recommended
course of action will be proposed for patent practitioners to follow to ensure that
patent applications that they work on satisfy the enablement requirement under U.S.
Patent Law.

embodiments.”).
9 Id.
10 Id.
11 Compare Genentech v. Novo Nordisk 108 F.3d 1361, 1365–68 (Fed. Cir. 1997) (holding patent
not enabling when subject invention shown by embodiments to be reduced to practice only in E. coli
bacteria), with Spectra-Physics, Inc. v. Coherent, Inc., 827 F.2d 1524, 1533 (Fed. Cir. 1987) (holding
that a patent need only disclose a single embodiment to satisfy enablement).
12 See Chiron v. Genentech, 363 F.3d 1247, 1254-1256 (Fed. Cir. 2004) (holding claims invalid
when they included two different antibodies and disclosure fell short of providing a specific and
useful teaching through embodiments of all antibodies within the scope of the claims).
13 Ariad Pharms. v. Eli Lilly, 598 F.3d 1336, 1350 (Fed. Cir. 2010) (When a genus of a
biomolecule is claimed in a patent, adequate written description of representative species of the
biomolecules themselves is required in the specification.); see also Noelle v. Lederman, 355 F.3d
1343, 1349 (Fed. Cir. 2004) (Antibodies can be claimed in terms of their binding affinity to an
antigen only if that antigen is fully characterized by its structure, formula, chemical name, and
physical properties.).
14 See Amgen v. Hoechst Marion Roussel, 314 F.3d 1313, 1336 (Fed. Cir. 2003) (Enablement was
satisfied when the specification was “buttressed by numerous post filing publications that
demonstrated the extent of the enabling disclosure.”).
15 See id.
16 See id.
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II. BACKGROUND
35 U.S.C. §112(a) requires that a disclosure of “the manner and process of
making and using [an invention]” in a written description, namely a patent
specification, must be “in such full, clear, concise, and exact terms as to enable any
person skilled in the art” to practice the full scope of the invention.17 A specification
is not enabling if a PHOSITA would not be able to practice the subject invention
without “undue experimentation.”18 Since 1988, the Federal Circuit uses eight
probative Wands factors to determine whether a specification requires undue
experimentation.19 Although the factors are “illustrative, not mandatory,”20 the
Federal Circuit follows the spirit of the factors in its opinions.21
Satisfying enablement becomes complicated in view of two co-existing lines of
cases that set seemingly opposite standards. Historically, the Federal Circuit has
ruled that disclosure of a single embodiment is sufficient to enable a broad claim in
the applied sciences.22 More recently, the Federal Circuit held that multiple
examples, or illustrative embodiments, are necessary to enable the full scope of a
claimed invention.23 The latter group of cases often involves inventions in the
unpredictable arts, like chemistry, biotechnology, and pharmaceuticals, wherein a
slight variation in method can yield unpredictable results or may not work at all.24
In Sitrick v. Dreamworks, LLC, the Federal Circuit began reconciling the previous
17 35 U.S.C. §112(a); see also The Manual of Patent Examining Procedure (“MPEP”) §§ 2164,
2164.01(a–b) (Enablement requires the specification to describe how to make and use the full scope
of the claimed invention without undue experimentation.).
18 In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).
19 Id. The Wands factors are: (1) the quantity of experimentation necessary; (2) the amount of
direction or guidance presented; (3) the presence or absence of working examples; (4) the nature of
the invention; (5) the state of the prior art; (6) the relative skill of those in the art; (7) the
predictability of the art; and (8) the breadth of the claims.
20 Amgen v. Chugai Pharm., 927 F.2d 1200, 1213 (Fed. Cir. 1991).
21 See Streck v. Research & Diagnostic Sys., 665 F.3d 1269, 1288 (Fed. Cir. 2012); Enzo
Biochem, Inc. v. Calgene, 188 F.3d 1362, 1371 (Fed. Cir. 1999); Genentech, 108 F.3d at 1365.
22 See Invitrogen v. ClonTech Labs., 429 F.3d 1052, 1071 (Fed. Cir. 2005) (holding that the
operable method of achieving the claimed invention was fully described in the patent specification,
distinguishing the case from precedent finding a lack of enablement in view of a failure to disclose
any way of practicing a claimed invention); CFMT v. Yieldup, 349 F.3d 1333, 1338 (Fed. Cir. 2003);
Johns Hopkins Univ. v. CellPro, 152 F.3d 1342, 1355, 1359, 1361 (Fed. Cir. 1998); Spectra-Physics,
827 F.2d at 1533; In re Rasmussen, 650 F.2d 1212, 1215 (C.C.P.A. 1981); In re Marzocchi, 439 F.2d
220, 223 (C.C.P.A. 1971).
23 Auto. Techs. v. BMW et al., 501 F.3d 1274, 1281–83 (Fed. Cir. 2007) (Claims to a side-impact
crash sensor for automobile airbags were improperly construed broadly in view of the single example
provided in the specification, which disclosed only a mechanical sensor when the claims also covered
an electrical sensor.); Liebel-Flarsheim v. Medrad, 481 F.3d 1371, 1378–79 (Fed. Cir. 2007) (Claims
to a high-pressure medical injection system held invalid and could not cover a similar invention sold
by the alleged infringer with a jacketless injector, because the specification recited specifically an
injector with a pressure jacket.); AK Steel, 344 F.3d at 1243–44 (Claims covering a Type 1 or Type 2
aluminum coating were deemed as non-enabling because the specification only described a Type 2
coating, thus causing undue experimentation to fill in the gaps.); In re Cavallito, 282 F.2d 363, 367
(C.C.P.A. 1960).
24 See, e.g., Enzo Biochem, 188 F.3d at 1374–77 (Although specifications may outline the
theoretical application of a technique in a wide variety of organisms, the practical application of the
claimed technique may involve many variables that scientists do not yet understand, thereby
making the actual practice of the technique unpredictable.).
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distinct sets of rulings, holding that the patent disclosure must enable the full scope
of the claimed invention, regardless of how many embodiments it takes.25 Thus,
broadly construed claims are subject to invalidation if the claims are supported by a
narrow disclosure.26
Enabling broadly construed claims is easier said than done. The complexities
inherent in biotechnology patents make such an endeavor difficult because a patent
applicant cannot broadly claim an invention if in reality, only part of that invention
is enabled.27 Broad claims to a method for producing any mammalian peptide of
interest in a plant cell need support from embodiments that show how to practice
that method in both monocots and dicots.28 The same idea applies to antisense
technology claimed to apply in a wide range of organisms,29 recombinant DNA
plasmids encoding for non-nascent human insulin claimed to be expressed in
microorganisms,30 live vaccines claimed to target any pathogenic RNA virus,31 and
gene expression vectors claimed to be transformable in hundreds of species of
cyanobacteria.32
Inclusion of too many or all possible embodiments of a claimed invention in
order to demonstrate support for every species covered by the claims, however, is not
a feasible course of action either.33 Complete disclosure would require a patent
25 See Sitrick v. Dreamworks, LLC, 516 F.3d 993, 1000 (Fed. Cir. 2008) (Claims to a method of
integrating a user’s audio signal or video image were broad enough to cover both movies and video
games, so the patent specification must enable both embodiments.).
26 Id.; see also In re ’318 Patent Litigation, 583 F.3d 1317, 1324–25, 1327 (Fed. Cir. 2009).
27 See, e.g., In re Goodman, 11 F.3d 1046, 1050 (Fed. Cir. 1993) (holding that a patent
specification containing a single example of producing gamma-interferon protein in only one dicot
plant species, tobacco, does not enable a biotechnician of ordinary skill in the art to produce any type
of mammalian protein in any type of plant cell).
28 See id.; see also Plant Genetics Sys. V. Dekalb Genetics, 175 F.Supp 2d 246, 256–59, 264–65
(D. Conn. 2001) (Like In re Goodman, a patent specification disclosing an Agrobacterium-mediated
transformation method that works only in dicot plant cells does not enable a broad claim of
transformation purported to cover all plant cells, including monocots and dicots, because a
significant amount of experimentation is needed beyond what is taught in the specification to secure
stable insertion of a heterologous gene into monocot plant cells.).
29 See Enzo Biochem, 188 F.3d at 1372–74 (Where claims are broadly drafted to encompass
application of a highly unpredictable antisense RNA technology in a wide range of cells, both
eukaryotic and prokaryotic, but the patent specification only taught the practice of antisense
technology to control expression of three specific genes in E. coli bacteria, the patent does not
broadly enable the use of antisense technology in all cells.).
30 See Regents of the Univ. of California v. Eli Lilly, 119 F.3d 1559, 1566–68 (Fed. Cir. 1997) (A
description of rat insulin cDNA is not a description of the cDNA of all the broad classes of vertebrate
and mammalian insulin; to enable such an invention, an adequate description of the claimed DNA
molecule is required, such as cDNA of the recombinant plasmids, written as a precise definition,
such as by structure, formula, chemical name, or physical properties, and not as a mere wish or plan
for practicing the claimed invention.).
31 See In re Wright, 999 F.2d 1557, 1562, 1564 (Fed. Cir. 1993) (Claims to methods of producing
non-pathogenic live vaccines against any pathogenic RNA virus that can be used to protect all living
organisms against that virus, need support in the disclosure of examples of an entire range of
vaccines shown to be in vivo immune-protective to a variety of RNA viruses in humans.).
32 See Vaeck, 947 F.2d at 490, 492–93, 495 (Claims to bacteria-derived chimeric genes for
transformation and expression in one hundred and fifty different genera of cyanobacteria hosts were
found to be not enabled when the specification disclosed, through nine examples, successful
transformation of the chimeric genes in only one particular species of cyanobacteria.).
33 In re Angstadt, 537 F.2d 498, 502–03 (C.C.P.A. 1976).
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application to have thousands of examples, forcing an inventor to carry out an
unreasonably large number of experiments.34 In an unpredictable technology,
inclusion of a large number of very similar embodiments would also not enable a
broadly claimed invention.35
Recently, in Amgen v. Sanofi, U.S. Patent No. 8,829,165 (“’165 patent”) was
nearly invalidated for lack of enablement despite disclosing a large number of
embodiments in support of its claims.36 The ’165 patent relates to an antigen binding
protein, namely a monoclonal antibody, that specifically binds to Proprotein
Convertase Subtilisin Kexin Type 9 (“PCSK9”).37 Forty-one examples were disclosed
in the specification in support of the patent claims.38 The application for the ’165
patent was filed on April 10, 2013 as a continuation of U.S. Patent No. 8,030,457,
from which the forty-one embodiments originated.39 The examples disclosed all
possible aspects of the invention, known at the time of filing, for antigen binding
proteins that bind to PCSK9.40
Amgen v. Sanofi was remanded for a new trial on several issues, including
sufficiency of disclosure for enabling the ’165 patent.41 With respect to patent
prosecution, the patent-in-suit raises an important question: what kinds of examples
should be disclosed when forty-one of them may not be enough to meet the
enablement requirement?
Id.
See Glaxo Wellcome v. Eon Labs Mfg., No. 00 Civ. 9080 (LMM), 2002 U.S. Dist. LEXIS 14950,
at *1, *3–5 (S.D.N.Y. Aug. 13, 2002).
36 See Sanofi, 872 F.3d at 1371–72.
37 U.S. Patent No. 8,829,165.
38 Id. at cols. 73–124.
39 Id.; see also U.S. Patent No. 8,030,457, claiming:
1. An isolated neutralizing antigen binding protein that binds to a PCSK9
protein comprising the amino acid sequence of SEQ ID NO:1, wherein the
neutralizing antigen binding protein comprises:
A heavy chain polypeptide comprising the following
complementarity determining regions (CDRs): a
heavy chain CDR1 that is a CDR1 in SEQ ID NO:49; a
heavy chain CDR2 that is a CDR2 in SEQ ID NO:49; a
heavy chain CDR3 that is a CDR3 in SEQ ID NO:49
and a light chain polypeptide comprising the
following CDRs: a light chain CDR1 that is a CDR1
in SEQ ID NO:23, a light chain CDR2 that is a CDR2
in SEQ ID NO:23; and a light chain CDR3 that is a
CDR3 in SEQ ID NO:23.
Parent patent claims an isolated monoclonal antibody that binds to PCSK9 via at least one or
two of its amino acid residues, thereby blocking the binding of PCSK9 to low density lipoprotein
receptor (“LDLR”) by 80% efficacy, the result of which is reduced levels of low-density lipoprotein
cholesterol (“LDL-C”) in patients.
40 U.S. Patent No. 8,829,165, claiming:
1. An isolated monoclonal antibody, wherein, when bound to PCSK9, the
monoclonal antibody binds to at least one of the following residues: S153, I154, P155,
R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ
ID NO:3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR.
(subject patent directed to a genus of antibodies that bind to specific amino acid residues on
PCSK9 that block it from binding to LDLRs, thereby resulting in reduced LDL-C levels in patients
with high cholesterol).
41 See Sanofi, 872 F.3d at 1371, 1375, 1381.
34
35
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Arising from a patent dispute in another recent case, this one before the
Supreme Court,42 U.S. Patent No. 8,598,219 (“’219 patent”) relates to a shelf-life
stable intravenous formulation of palonosetron hydrochloride for the treatment of
nausea and vomiting symptoms after emetogenic chemotherapy.43 Application for
the ’219 patent was filed on May 23, 2013 as a continuation-in-part of U.S. Patent
No. 7,947,724 (“’724 patent”).44
The ’724 patent initially described seven
embodiments of the drug and an eighth embodiment describing a different
formulation was submitted as part of the specification filed for the ’219 patent.45
Although the ’219 and ’724 patents were considered on issues other than
enablement,46 it would nevertheless be interesting and informative to examine the
enablement issue because it is not so clear which embodiments of the formulations,
as claimed, can have a shelf life of either twenty-four or eighteen months.47 If it were
disclosed which embodiments spoke to the stability aspect of the claimed invention,
42 See Helsinn Healthcare v. Teva Pharm. USA, No. 17-1229, slip op. at 1, 1–2 (U.S. January 22,
2019), aff’g 855 F.3d 1356, 1360–61, 1363, 1367 (Fed. Cir. 2017) (involving U.S. Patent No. 8,598,219
and other related patents, this case dealt with issues relating to the on-sale bar under the America
Invents Act (“AIA”), but the subject patent was previously subject to an enablement challenge in a
post-grant review case, Accord Healthcare v. Helsinn Healthcare (P.T.A.B. 2013) (settled without
decision Sept. 2, 2014), before the Patent Trial and Appeal Board (“PTAB”)).
43 U.S. Patent No. 8,598,219 (filed as a continuation-in-part of U.S. Patent No. 7,947,724,
adding an eighth example of the subject invention, a palonosetron hydrochloride pharmaceutical
injection, to the patent specification in support of the elements relating to the drug’s stability
claimed in independent claims 1 and 8).
44 Id.; see also U.S. Patent No. 7,947,724, claiming:
1.A pharmaceutically stable intravenous solution for reducing emesis or
reducing the likelihood of emesis comprising:
from 0.03 mg/ml to 0.2 mg/ml palonosetron or a pharmaceutically
acceptable salt thereof, buffered at a pH of from 4.0 to 6.0; and a
pharmaceutically acceptable sterile aqueous carrier including a
tonicifying effective amount of mannitol and from 0.005 mg/ml to 1.0
mg/ml EDTA.
(Whereas the subject patent claimed a pharmaceutical single-use dose
of the same formulation at a certain range of concentrations, and being stable for
twenty-four months, or alternatively eighteen months, when stored at room
temperature.).
45 Compare U.S. Patent No. 7,947,724 with U.S. Patent No. 8,598,219, which claims:
1.A pharmaceutical single-use, unit-dose formulation for intravenous
administration to a human to reduce the likelihood of cancer chemotherapyinduced nausea and vomiting, comprising a 5 mL sterile aqueous isotonic
solution, said solution comprising:
palonosetron hydrochloride in an amount of 0.25 mg based on the
weight of its free base; from 0.005 mg/mL to 1.0 mg/mL EDTA; and from
10 mg/mL to 80 mg/mL mannitol, wherein said formulation is stable at
24 months when stored at room temperature.
(emphasis added) (Compared to the parent patent, the subject patent
describes a third formulation of the drug, as an additional eighth embodiment,
comprising slightly different reagents and a plastic container plus rubber stopper
closure system presumably for increased shelf life.).
46 Helsinn, No. 17-1229 at 1–2, aff’g 855 F.3d at 1363, 1367 (The issue decided on certiorari is
“whether . . . an inventor’s sale of an invention to a third party that is obligated to keep the
invention confidential qualifies as prior art for purposes of determining the patentability of the
invention.”).
47 See U.S. Patent No. 8,598,219.
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and the addition of the eighth embodiment as post filing data did in fact help close
the gap in disclosure, how exactly would that be achieved?48
Clarifying this dilemma inevitably leads to answering the big question: exactly
what kind of disclosure is sufficient to satisfy the enablement requirement under 35
U.S.C. §112(a)?49 Admittedly, this is too enormous of a question to tackle in a
comment. Hence, elucidation and resolution of this standing conflict in patent
enablement will be attempted from the perspective of post filing data.50
Post filing data is evidence generated after the filing date of the patent
application that is used to demonstrate an enabling disclosure.51 Post filing evidence
may incorporate advances that would make the disclosure presently enabling, even
though it was not clearly enabled as of the filing date.52 Post filing technical evidence
demonstrating enablement can come in various forms.53 It can be sorted into three
basic categories: (1) affidavits reflecting what occurred prior to filing of the
application; (2) post filing generated technical evidence demonstrating that the
claimed invention is not enabled; and (3) post filing generated technical evidence that
the invention does have utility or that the disclosure is enabling.54 In a prosecution
context, the inventor may still be working on developing the invention, so there may
be additional post filing evidence generated that could be used to support the
enabling disclosure.55
However, use of post filing data can go awry. Enzo Biochem v. Calgene sees the
patent holder present post filing data to demonstrate enablement in the wrong way.56
The post filing data, in the form of a declaration, made conclusory statements and
included only routine experimentation.57 It provided nothing in the form of new
information to support the disclosure of the claimed invention.58
See id.
See 35 U.S.C. §112(a).
50 See In re Brana, 51 F.3d 1560, 1566–67 (Fed. Cir. 1995) (allowing post filing data to
substantiate any doubts as to the asserted [claims] since [it] pertains to the accuracy of a statement
already in the specification).
51 See id. at 1565, 1567 (specification disclosing an anti-tumor drug described the claimed
compounds as having “a better action and a better action spectrum as antitumor substances” than
known compounds tested in vivo for anti-tumor activities in two lymphocytic leukemia tumor
models, but it was deemed non-enabling so the patent applicant submitted a declaration that listed
anti-tumor activity test results of the claimed compounds in the same leukemia tumor models,
showing that the claimed invention would likely be useful as anti-cancer agents as disclosed in the
specification).
52 Id. at 1567 (The declaration can be used to support the accuracy of statements already made
in the patent specification about the claimed invention.).
53 Id. (The declaration was filed after the filing date of the patent application to prove that the
disclosure found therein was enabling at the time of filing, but not to render an insufficient
disclosure enabling after filing.).
54 See In re Hogan, 559 F.2d 595, 602, 604–06, 608–09 (C.C.P.A. 1977).
55 See Brana, 51 F.3d at 1567 (The “declaration, though dated after applicants’ filing date, can
be used to substantiate any doubts as to the asserted utility since it pertains to the accuracy of a
statement already in the specification.”).
56 Enzo Biochem, Inc. v. Calgene, Inc., 188 F.3d 1362, 1375–76 (Fed. Cir. 1999) (A declaration
was submitted to the USPTO after the subject patent applications were rejected ten times on the
ground of non-enablement due to a concern that antisense technology was too unpredictable to be
practiced in cells other than E. coli without some enabling disclosure in those other types of cells.).
57 Id. (The declaration made largely conclusory assertions of enablement about the claimed
invention and provided mere routine experimentation based on the written descriptions in the
48
49
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Post filing data is a limited solution that can only be invoked carefully during
patent prosecution to convince a USPTO patent examiner that the broad claims are
fully supported by the existing disclosure of the patent specification.59 Because it is
limited, post filing data can only fill in the gaps between the claimed invention and
the specification to a certain degree, the extent of which will help define what a
patent applicant must disclose in a specification to satisfy the enablement
requirement.
One must keep in mind the big picture, which is the scope of enablement must
correlate with the scope of the claims.60 Thus, proper inquiry when using post filing
data to fill in gaps in disclosure is whether the post filing data can do so such that
there will be reasonable correlation between the scope of enablement in the
disclosure and the scope of the claims.61
III. ANALYSIS
The number of embodiments disclosed in a patent application deemed by the
Federal Circuit to be sufficient to enable the invention claimed therein has fluctuated
to both extremes.62 When examples of an invention are completely absent from a
specification, such disclosure only proposes an unproven hypothesis, and is clearly
not enabling.63 However, when patent claims are construed more broadly than the
examples disclosed in the specification, the Federal Circuit has vacillated over the
years about the number and types of disclosures that satisfy the enablement
requirement.64
patent specifications.).
58 See id.
59 Gould v. Quigg, 822 F.2d 1074, 1077–79 (Fed. Cir. 1987).
60 Leonard v. Maxwell Motor Sales, 252 F. 584, 589-90 (2d Cir. 1918) (Judge Learned Hand
addressed the ability to draw generalizations not expressly supported by a disclosure.).
61 See Vaeck, 947 F.2d at 495 (“There is no reasonable correlation between the narrow disclosure
in [the applicants’] specification and the broad scope of protection sought in the claims encompassing
gene expression in any or all cyanobacteria.”); see also Wands, 858 F.2d at 736-37; In re Fisher, 427
F.2d 833, 839 (C.C.P.A. 1970) (noting the first paragraph of §112 requires that the scope of
protection sought bears a reasonable correlation to the scope of enablement provided in the
specification).
62 Compare Invitrogen, 429 F.3d at 1071 (holding that “the enablement requirement is met if
the description enables any mode of making and using the claimed invention”), Johns Hopkins, 152
F.3d at 1360–61 (The disclosure of a single embodiment of producing an anti-My-10 antibody is
deemed sufficient to enable the broader genus of claimed antibodies.), with Auto. Techs., 501 F.3d at
1283 (holding that knowledge of a PHOSITA cannot fill in deficiencies in disclosure of a single
embodiment of a mechanical crash sensor invention, when the subject patent also claimed an
electrical crash sensor), Sitrick, 516 F.3d at 1000 (holding that PHOSITA could not take the singleexample disclosure of the subject patent and practice the claimed invention without undue
experimentation), and Chiron, 363 F.3d at 1254 (holding that disclosure of embodiments to a
monoclonal antibody that binds human c-erbB-2 antigen, a nascent technology at the time, fell short
of providing a “specific and useful teaching” of the two different antibodies claimed in the patent).
63 ’318 Patent Litigation, 583 F.3d at 1327 (’318 patent did not have any examples of what
constituted the subject invention, rather it merely “state[d] a hypothesis and propose[d] testing to
determine the accuracy of that hypothesis.”); see also U.S. Patent No. 4,663,318.
64 Compare Hoechst, 314 F.3d at 1335–36 (Patent claims found to be enabling although
construed more broadly than the single example disclosed in the patent specification, because the
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As recently as 2012, specifications disclosing a single embodiment were found to
sufficiently enable a claimed invention because the knowledge of a PHOSITA can fill
in any remaining gaps in disclosure.65 The Federal Circuit decided that any
complications that a PHOSITA may encounter while practicing the full scope of a
claimed invention can be dispelled by simply following the teachings within the
patent.66 By doing so, the PHOSITA can avoid undue experimentation.67
At the same time, “a patentee who chooses broad claim language must make
sure the broad claims are fully enabled.”68 When there are distinct aspects or
variations of a claimed invention of equal or mutual significance, disclosure of
multiple embodiments describing each of those aspects or variations is necessary to
enable the full scope of the patent.69 In Sitrick, claims relating to the integration of
audio signals or video images were construed to include both movies and video
games.70 However, the court found the claims to be non-enabling because the
specification failed to disclose embodiments describing integration of user images in
movies, teaching the invention only in relation to video games.71 Likewise, in Chiron,
the scope of the claims in the patent-in-suit included two different antibodies.72 The
court also found these claims to be non-enabling because the specification did not
teach all of the antibodies within the scope of the claims, and the antibody technology
was too nascent for a PHOSITA to have knowledge to fill in the gaps in disclosure.73
Thus, rather than trying to draft a specific number of embodiments to achieve the
goal of sufficient disclosure in a patent specification, it is more important to describe
embodiments for each key aspect or variation of an invention, as set out in the patent
claims, in order to satisfy 35 U.S.C. §112(a).74
This qualitative, rather than quantitative, approach to disclosure in patent
specifications makes sense in view of the apparent dilemma relating to the lack of
court looked to not only the disclosure providing a method of making and using the invention, but
also what was known in the art to fill in any gaps in the disclosure.), and Streck, 665 F.3d at 1291
(finding that “no undue experimentation would be necessary once the teachings of the subject patent
were known,” the court held the patent claims to be enabling despite being construed more broadly
than the single embodiment disclosed in the specification), with Auto. Techs., 501 F.3d at 1283
(Patent claims held to be not enabling when construed more broadly than the example disclosed,
because the court found that practicing the full scope of the claimed subject invention would require
undue experimentation, since knowledge of a PHOSITA cannot supply the missing information
where the specification should supply novel aspects of the invention.), and Liebel-Flarsheim, 481
F.3d at 1380 (Claims held to be not enabling when construed to include a single embodiment
disclosed in the specification as well as a second alternative embodiment, especially when the
specification provided no guidance as to how to make or use the alternative embodiment and even
taught away from the alternative embodiment.).
65 Streck, 665 F.3d at 1289.
66 Id. at 1291.
67 Id.
68 Sitrick, 516 F.3d at 999.
69 See Chiron, 363 F.3d at 1256 (Although an aspect of the claimed invention included binding of
an antibody to a breast cancer antigen, the patent disclosure only enabled murine antibodies and
fell short of providing a specific and useful teaching of all antibodies, particularly chimeric
antibodies, within the scope of the claimed invention.).
70 516 F.3d at 999.
71 See id. at 999–1000.
72 See 363 F.3d at 1250-51.
73 Id. at 1254-56.
74 See 35 U.S.C. §112(a).
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enablement of the ’165 patent at issue in Amgen v. Sanofi.75 Briefly, the ’165 patent
invention comprises: 1) an antigen binding protein in the form of an isolated
monoclonal antibody that competitively or selectively binds to PCSK9 at the location
of at least four of PCSK9’s amino acid residues such that the antibody reduces
binding of LDLR to PCKS9 by at least eighty percent; and 2) a pharmaceutical
composition of the antigen binding protein that may be coupled with an active agent
for administration in patients seeking treatment for high cholesterol or LDL levels in
their blood serum.76 A method of making the recombinant antigen binding protein,
by injection of vector molecules that transfer coding information of the protein into
host cells for inducing production of the protein, was disclosed in the specification but
not claimed in the ’165 patent.77
The ’165 patent lists the full range of various possible amino acid sequences of
the antigen binding protein.78 In addition, figures show the structure of PCSK9, the
structures of the various possible heavy chain and light chain portions of the antigen
binding protein, the binding efficiency of the antigen binding protein to PCSK9, and
its effect on PCSK9 and LDL.79 Numerous embodiments of the invention describe
the possible amino acid sequences and combinations of heavy chain and light chain
segments of the antibody,80 the possible types of antibodies that the antigen binding
protein can be,81 the range of pharmaceutical formulations using the antigen binding
protein,82 the function of the antigen binding protein,83 and the effect of the
pharmaceutical formulations.84
The forty-one specific examples detail the
See Amgen v. Sanofi, 872 F.3d at 1372–73, 1375; U.S. Patent No. 8,829,165.
See U.S. Patent No. 8,829,165 cols. 3–124.
77 Compare id. at cols. 7, 45–49, 73–77, and 81–84, with id. at cols. 427–430.
78 Id. at cols. 123–428 (SEQ ID NOS: 1-575); see also id. at cols. 3–17, 40–42, 47, 50, 60–63, 85,
104–05, 110–11, and 122.
79 Id. at figs. 4A–12F, 14A–14B, 16A–21D, 23A–25F, and 27A–28D.
80 Id. at cols. 3–6, and 12–17. For example:
In some aspects, the invention comprises an isolated antigen binding protein that binds
PCSK9 comprising: A) one or more heavy chain complementary determining regions (CDRHs)
selected from the group consisting of: (i) a CDRH1 from a CDRH1 in a sequence selected from the
group consisting of SEQ ID NO: 74, 85, 71 . . . In some embodiments, the isolated antigen binding
protein comprises at least one CDRH of A) and at least one CDRL of B). In some embodiments, the
isolated antigen binding protein comprises at least two CDRH of A) and at least two CDRL of B).
81 Id. at cols. 6–7. For example:
In some embodiments, the isolated antigen binding protein is a monoclonal antibody, a
polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, a chimeric
antibody, a multi-specific antibody, or an antibody fragment thereof. . . . In some embodiments, the
isolated antigen binding protein is a human antibody. In some embodiments, the isolated antigen
binding protein is a monoclonal antibody. In some embodiments, the isolated antigen binding
protein is of the IgG1-, IgG2-IgG3- or IgG4-type. In some embodiments, the isolated antigen binding
protein is of the IgG4- or IgG2-type.
82 Id. at cols. 7–9. For example:
In some aspect, the invention comprises a pharmaceutical composition comprising at least
one antigen binding protein as described herein and a pharmaceutically acceptable excipient. In
some embodiments, the pharmaceutical composition further comprises an additional active agent. In
some embodiments, said additional active agent is selected from the group consisting of a
radioisotope, radionuclide, a toxin, or a therapeutic and a chemotherapeutic group.
83 Id. For example:
In some aspects, the invention comprises an isolated antigen binding protein that competes
for binding to PCSK9 with an antigen binding protein disclosed herein.
84 Id. For example:
75
76
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generation, optimization, and functional characterization of the antigen binding
protein.85
It is undeniable that the ’165 patent discloses a lot of information about the
claimed invention.86 However, nowhere in the abundance of information does the
specification describe how the antigen binding protein definitively binds to PCSK9.87
The best it does is estimate all of the possible locations on PCSK9 at which the
antigen binding protein can bind in relation, measured by Angstrom, to any one of
the four hundred and seventeen amino acid residues 31–447 on PCSK9.88 Yet, the
’165 patent claims many times over that “the isolated monoclonal antibody binds to
at least” one of numerous amino acid residues on PCSK9.89
In view of hundreds of possibilities of where the antigen binding protein can
bind to PCSK9, a PHOSITA would not be able to practice this invention without
undue experimentation. Moreover, the specification provides no guidance regarding
exactly how the antigen binding protein is supposed to bind to PCSK9,90 so a
PHOSITA would likely not be successful in achieving the outcome intended by the
inventor when practicing this invention. The fact that forty-one examples are
disclosed in the specification is immaterial if they all teach around the key aspect of
the invention recited in the claims. Thus, silence on the mechanism of binding
between the antigen binding protein and PCSK9 critically renders the ’165 patent
non-enabling.
The inventors of the ’219 patent, on the other hand, sought to add an eighth
embodiment to their continuation-in-part patent application derived from their
parent patent in which only seven embodiments were disclosed.91 The eighth
example in the ’219 patent is an additional formulation of the liquid injectable
palonosetron invention that is different from the other two formulations in that it
does not comprise of the tonicifying agent, mannitol.92
Instead, the eighth
In some aspects, the invention comprises a neutralizing antibody that binds to PCSK9 and
reduces a low density lipoprotein receptor (LDLR) lowering effect of PCSK9 on LDLR.
85 Id. at cols. 73–124 (The forty-one examples include immunization and titering of the hybrid
mice producing the antibodies, generation of hybridomas, selection of antibodies to PCSK9,
production of recombinant human antibodies and hybridomas, sequence analysis of the heavy and
light chains of the produced antibodies, characterization of the antibodies’ ability to bind PCSK9,
efficacy assay to see how well the antibodies block LDLR from binding PCSK9, detection of levels of
serum cholesterol in mice before and after treatment with the antibody, tracking the effect of the
antibody on serum cholesterol over time, and testing treatment using the antibody in human
patients.).
86 See id. at 1–124.
87 See id.
88 Id. at cols. 9–12. For example:
In some aspects, the invention comprises a neutralizing antigen binding protein that binds to
PCSK9, wherein the antigen binding protein binds to PCSK9 at a location within residues 31-447 of
SEQ ID NO: 3. In some embodiments, when the antigen binding protein is bound to PCSK9, the
antibody is positioned 8 angstroms or less from at least one of the following residues of PCSK9:
S153, I154, P155, R194 . . . In some embodiments, the antibody is positioned 5 angstroms or less
from at least one of the following residues of PCSK9: S153, I154, P155, R194, D238, A239, I369,
S372, D374, C375, T377, C378, F379, V380, or S381.
89 Id. at cols. 427–430 (Almost all of the patent claims recite a binding connection between the
isolated monoclonal antibody and at least one amino acid residue on PCSK9.).
90 See id. at 1–124.
91 Compare U.S. Patent No. 8,598,219 cols. 7–9, with U.S. Patent No. 7,947,724 cols. 7–9.
92 Id.
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embodiment’s formulation relies on sodium chloride as the tonicifying agent.93 This
seems contrary to the third example, originating from the parent patent, which
teaches away from using sodium chloride by disclosing adding mannitol as providing
“superior stability” for the palonosetron solution.94
Regardless, having a palonosetron formulation without mannitol in the
specification does not make the ’219 patent immune to enablement challenges. The
purpose of disclosing embodiments with different formulations was to show that
various palonosetron solutions can maintain their stability under varying conditions
of temperature and light when stored on the shelf for eighteen to twenty-four
months.95 However, the specification seems to provide no example or support for the
claims reciting that the palonosetron solutions are stable at room temperature for
such periods of time.96
Following the reasoning above as applied to the ’165 patent, a PHOSITA may be
able to practice the invention here. But there is no guarantee that the outcome will
be as intended by the inventors, because no proof was given in the specification that
any of the palonosetron formulations were shelf-stable at room temperature for over

93

U.S. Patent No. 8,598,219 col. 9.
Example 8
Formulation III
The following is a representative pharmaceutical formulation and container closure for
palonosetron that is useful for intravenous infusion formulations.
Ingredient
Amount (mg)
Palonosetron Hydrochloride

0.75

Sodium Chloride

450.0

EDTA

2.5

Sodium citrate

18.5

Citric acid monohydrate

7.8

WFJ

q.s. to 50 mL

Sodium hydroxide solution and/or
hydrochloric acid solution

pH 4.8 ± 0.5

Container closure system

94

95
96

plastic container plus rubber stopper
(isoprene)

U.S. Patent No. 7,947,724 col. 7.
Example 3
Tonicifying Agent
Formulations of palonosetron hydrochloride in citrate buffer were prepared including
either a) sodium chloride or b) mannitol. The palonosetron hydrochloride formulation
including mannitol showed superior stability. The optimum level of mannitol required for an
isotonic solution was found to be 4.15%. (emphasis added)
See U.S. Patent No. 8,598,219 cols. 7–9.
See id. at cols. 1–9.
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eighteen or twenty-four months.97 In the end, the PHOSITA would still need to carry
out undue experimentation when practicing the invention in order to achieve the
intended outcome. Thus, if the issue of enablement were presented on writ of
certiorari for the ’219 patent in the case between Helsinn and Teva,98 patent owner
Helsinn would likely not have been able to overcome an argument of the ’219 patent
being non-enabling, unless a further continuation-in-part application were filed with
post filing experimental data.
Although it may be clearer what should not be done when enablement is at
issue, the question of what can be done is more difficult to figure out. Post filing data
is a helpful but limited solution to fill in any unexpected gaps in disclosure after a
patent application has already been filed. Post filing data should not be used
incorrectly to introduce any new matter into the existing patent application.99
In fact, patent applicants should be aware that the determination of what kind
of post filing data may be used to prove that a specification is enabling rests on facts
surrounding a patent at issue and its existing disclosure, in view of 35 U.S.C. §
112(a).
They should bear in mind that § 112(a) provides two interrelated
requirements: that the written description describes what the subject invention is
and how it works; and that the description enables a PHOSITA to practice the
invention purely based on reading the specification.100 Brana allows post filing data
only to “substantiate any doubts” as to what is asserted in the patent because it
relates to the accuracy of a statement already existing in the specification.101
Consequently, if disclosures about an aspect of a claimed invention are missing from
the specification, there would be no way to add in new matter after filing of the
patent application to fill that void.102 In Brana, test data was submitted and
accepted during patent prosecution to support a statement already made in the

See id.
See Helsinn, No. 17-1229 at 1–2, aff’g 855 F.3d at 1363, 1367 (The issue on certiorari related
to the on-sale bar under the AIA.).
99 See Rasmussen, 650 F.2d at 1214 (broadening a claim under 35 U.S.C. § 112 does not add new
matter to the disclosure in the specification, which is prohibited under 35 U.S.C. § 132, because
disclosure is that which is taught, not that which is claimed); see also MPEP § 2163(I)(B) (holding
that proscription against the introduction of new matter into a patent application serves to prevent
a patent applicant from adding new information that goes beyond the subject matter originally
filed).
100 See 35 U.S.C. § 112(a); MPEP § 2164 (showing that enablement requires the specification to
describe how to make and use the invention), whereas MPEP § 2161 is a separate and distinct
requirement from enablement (Written description requires that the specification describe the
claimed invention in sufficient detail that a PHOSITA can understand the invention and can
reasonably conclude that the inventor had possession of and actually invented the claimed invention
at the time of filing.).
101 See Brana, 51 F.3d at 1567 (A declaration submitted after the filing date of a patent
application showed the effect of a claimed anti-tumor drug in two different types of cancer, as
established in the patent specification.).
102 See ’318 Patent Litigation, 583 F.3d at 1325 (’318 patent claiming a method of treating
Alzheimer's disease with galanthamine did not contain anything of substance to describe what
constituted the invention, so there are no statements in the specification for post filing test data to
even support.); see also Brana, 51 F.3d at 1567.
97
98
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patent specification at the time of filing.103 Post filing data is also allowed for
purposes of confirming what is speculated in the specification.104
Post filing data can be considered for enablement challenges not when it is
offered for the purpose of adding knowledge of the art after a patent application is
filed, but when it is offered as evidence to show a level of ordinary skill in the art at
the time of filing.105 Given this, post filing data can be used to confirm and
substantiate results that were predicted in the specification at the time of filing.106
Its main purpose is to support the accuracy of or to help elucidate statements made
in the specification.107
So, post filing data may be generally admissible to prove the “state of the art” at
the time of filing, depending on the particular technology of the claimed invention.
Some experimental data missing from the specification at the time of filing may be
permissibly added using post filing data, because a PHOSITA would have been able
to extrapolate beyond the embodiments in the specification and interpolate between
them in order to fill in any gaps left by the once missing experimental data. Proof of
the “state of the art” at the time of filing in the mind of a PHOSITA would indicate
that the PHOSITA is able to understand or foresee the full scope of the claimed
invention from its initial or existing disclosure.108
Post filing data should not be seen as a catch-all for fixing insufficient
enablement, far from it in fact.109 It is essential to focus on disclosing all aspects of
an invention in the specification when drafting a patent application. If a claim covers
a range of embodiments, the disclosure must contain sufficient written description to
adequately enable the full scope of the range of embodiments.110 In other words, if a
claim reads on distinctly different embodiments of an invention, the specification
must sufficiently enable each of those embodiments.111

Brana, 51 F.3d at 1562.
Id. at 1567.
105 See Hogan, 559 F.2d at 605 (holding that the use of later submissions as evidence to show
the state of the art existing at the time of filing of the patent application is allowed).
106 See Brana, 51 F.3d at 1567.
107 Id.
108 See Marzocchi, 439 F.2d at 223–24 (holding that the breadth of the scope of a disputed term
“polyethyleneamine” in the claims of the patent-in-suit was sufficiently supported by disclosure of a
single example compound in the patent specification, because a PHOSITA would be able to
understand which chemical compounds the term encompasses, and thus what compounds the patent
covers, based on the PHOSITA’s own knowledge in the art).
109 See Cavallito, 282 F.2d at 367 (holding that a specification with nineteen examples
adequately enabled a broad claim covering hundreds of thousands of compounds because the
sufficiency of a disclosure depends not on the number, but rather on the nature of the claimed
compounds and the nature of the supporting disclosures).
110 See Liebel-Flarsheim, 481 F.3d at 1378 (establishing that the disclosure must teach the full
range of embodiments in order for the claims to be enabled).
111 See Auto. Techs., 501 F.3d at 1285 (An inference of “distinctly different” embodiments might
arise when the applicant provides substantial written description for one embodiment and relatively
little written description for another.).
103
104
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IV. PROPOSAL
It is important to remember that post filing data cannot be implemented to
supply what is missing from the description of an invention disclosed in a patent
specification.112 Rather, post filing data can only be used to support or further
explain the description of the invention that is already disclosed in the patent
specification.113 A patent applicant must possess all parts of the invention claimed at
the time of filing of the patent application.114
With this in mind, a patent specification should disclose at the outset all aspects
of the invention as claimed in at least the independent claims. By doing so, the
boundaries of disclosure contained within the four corners of the patent application
will cover all claimed aspects of the invention. In other words, when drafting, a
patent applicant should be certain that all necessary information supporting the
claims is disclosed or described in the patent specification with sufficient
particularity to ensure that a PHOSITA will be able to practice the invention and
understand or recognize that the patent applicant possessed the invention being
claimed at the time of filing.115 Otherwise, the specification may be deemed as nonenabling. Disclosure of all necessary information means that all essential or critical
features of the invention, as defined in the claims, are adequately described in the
specification, with the exception of certain features that are either conventionally or
feasibly known in the art.116
In the unpredictable arts,117 it is especially important for the patent
specification to sufficiently describe “distinguishing identifying characteristics” of the
invention in order to support the claims.118 To do so, a specification can show
reduction to practice by describing testing of the claimed invention or, in the case of
biological materials, by specifically describing a deposit.119
In the ’165 patent at issue in Amgen v. Sanofi, among forty-one examples
testing the binding of the antigen binding protein to PCSK9 described in the
specification, there is not one disclosure describing the mechanism of binding and the
location on PCSK9 to which the antigen binding protein actually binds.120 A patent
112 See MPEP § 2163(I)(B) (providing that “proscription against the introduction of new matter
into a patent application serves to prevent a patent applicant from adding new information that
goes beyond the subject matter that was originally filed”).
113 See Brana, 51 F.3d at 1563.
114 MPEP § 2163(I) (“[A]pplicant shows possession of the claimed invention by describing the
claimed invention with all of its limitations using such descriptive means as words, structures,
figures, diagrams, and formulas that fully set forth the claimed invention.” (quoting Lockwood v.
Amer. Airlines, Inc., 107 F.3d 1565, 1572 (Fed. Cir. 1997))).
115 MPEP § 2163(I)(A).
116 Id.
117 Enzo Biochem, 188 F.3d at 1372.
118 MPEP § 2163(I) (One must define a compound by "whatever characteristics sufficiently
distinguish it” from others.); see also Eli Lilly, 119 F.3d at 1568–69, and Chugai, 927 F.2d 1200 at
1206.
119 MPEP § 2163(I) ("[R]eference in the specification to a deposit may also satisfy the written
description requirement with respect to a claimed material" and “description of the deposited
material needs to be as complete as possible” such that “the more information provided about a
particular deposited biological material, the better the examiner will be able to compare the identity
and characteristics of the deposited biological material with the prior art.”).
120 See U.S. Patent No. 8,829,165 cols. 73–124.
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that claims as its invention a novel antibody that functions by competitively binding
to another protein should, at minimum, disclose how the antibody actually binds to
that target protein, unless such functions may be predictable in view of the teachings
of the specification.121 A patent applicant drafting an application for a novel protein
should aim to elucidate, through disclosure in the specification, the functional
mechanism of the novel protein if the function of that protein is a key aspect of the
claimed invention (it is, most of the time).
Similarly, nowhere in the specification of the ’219 patent is proof of stability of
the palonosetron formulation at eighteen or twenty-four months disclosed, even
though stability for those lengths of time are claimed as elements of the invention.122
The examples of different formulations of the drug do not describe testing of stability
of those different formulations under varying conditions of temperature, light, and
time spent on the shelf beyond fourteen days of storage.123 If the length of time that
a compound, pharmaceutical or otherwise, can remain stable on the shelf is claimed
as an element of the invention, then a patent application should disclose with
specificity the testing parameters under which the compound remains stable and for
how long remains stable.124 Other characterizations of compounds, such as molecular
weight, composition, solubility, crystal structure, chirality, and binding specificity
and affinity, claimed as an element of an invention should also be supported by
disclosures in the specification showing testing done to define such characteristics.125
While drafting a patent application, an applicant should focus on the scope of
the disclosures regarding each aspect of the claimed invention, rather than the
number of examples used to support the disclosures.126 After all, the scope of the
claims should be less than or equal to the scope of the enablement.127 If broad claims
are made, then the scope of the disclosures in the patent specification should provide
teachings of comparable breadth.128 At the same time, it is advisable to not disclose
too many details that would allow competitors to exploit the claimed invention
without putting in extra effort of their own. Thus, the scope of an enabling disclosure
should be just broad enough to sufficiently teach a PHOSITA how the claimed
invention should be carried out.
Although it is tempting to draft the disclosures as broadly as possible, by using
more general terms or statements to predict certain effects that may extend beyond
the disclosed invention, doing so without the proper support from test data would
only invite a patent examiner’s rejection of the patent application during

See id. at cols. 3–124, 427–30.
See U.S. Patent No. 8,598,219.
123 See id.
124 See id.
125 See Fisher, 427 F.2d at 839 (The patent at issue did not set forth with particularity the
chemical structure or adequate physical characteristics of an injectable adrenocorticotrophic
hormone concentrate to sufficiently identify its composition.).
126 See Chiron Corp., 363 F.3d at 1253 (An enabling disclosure of a specification must be
commensurate in scope with the claims under consideration.); Chugai, 927 F.2d at 1213 (The patent
disclosure must be sufficient enough to enable a PHOSITA to carry out the claimed invention
“commensurate in scope” with what is covered by the claims.).
127 Sitrick, 516 F.3d at 999.
128 Id. (“[A] patentee who chooses broad claim language must make sure the broad claims are
fully enabled.”).
121
122
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prosecution.129 Accordingly, an applicant should take care not to make such
unsupported general statements that go beyond the scope of the disclosed
embodiments, especially for an invention in the unpredictable arts.130
If a claimed feature or aspect of an invention is not described in sufficient detail
in the application upon filing, then post filing data may be used to supplement or
clarify what is already disclosed in the specification.131 Of course, the extent to which
post filing data can fill gaps in disclosure is limited, so it would not be wise to look to
post filing data as a total saving grace when a patent examiner rejects an application
due to non-enablement.132 Supplemental experimental data submitted after filing
should only serve a purpose of bridging the gap between a PHOSITA’s understanding
of the teachings already found in the specification and the PHOSITA’s own
knowledge in the art.133 As long as the patent specification is drafted properly and
addresses each aspect claimed of a subject invention, the post filing experimental
data may be used to elaborate on the subject matter already disclosed in the
specification.134
V. CONCLUSION
35 U.S.C. § 112(a) sets the standard for enablement of patent applications.135
Yet, putting this requirement into practice has not become straightforward over
129 See MPEP § 2163.03(V) (A “claim may lack written description support when (1) the claim
defines the invention in functional language specifying a desired result but the disclosure fails to
sufficiently identify how the function is performed or the result is achieved, or (2) a broad genus
claim is presented but the disclosure only describes a narrow species with no evidence that the
genus is contemplated” (quoting Ariad Pharms., 598 F.3d at 1349–50); and “the appearance of mere
indistinct words in a specification or a claim . . . does not necessarily satisfy that requirement.”
(quoting Enzo Biochem v. Gen-Probe, 323 F.3d 956, 968 (Fed. Cir. 2002))).
130 See Spectra-Physics, 827 F.2d at 1533 (Courts, until recently, were likely to uphold a broad
claim directed to inventions in the predictable arts, even if it encompassed other embodiments that
were inadequately disclosed.).
131 MPEP § 716.09 (Once an “examiner has established . . . lack of enablement, the burden falls
on the applicant to present persuasive arguments, supported by suitable proofs where necessary,
that one skilled in the art would have been able to make and use the claimed invention using the
disclosure as a guide” (quoting In re Brandstadter, 484 F.2d 1395 (C.C.P.A. 1973)); and “[e]vidence
to supplement a specification which on its face appears deficient . . . must establish that the
information which must be read into the specification to make it complete would have been known
to those of ordinary skill in the art.” (quoting In re Howarth, 654 F.2d 103, 106 (C.C.P.A. 1981))).
132 See id.
133 See MPEP § 716.09 (Affidavits or declarations presented to show that the disclosure of an
application is sufficient to one skilled in the art are not acceptable to establish facts which the
specification itself should recite, nor are affidavits or declarations purporting to explain the
disclosure or to interpret the disclosure of pending applications.).
134 Id.
135 35 U.S.C. § 112(a) (“[T]he specification shall contain a written description of the invention,
and of the manner and process of making and using it, in such full, clear, concise, and exact terms as
to enable any person skilled in the art to which it pertains, or with which it is most nearly
connected, to make and use the same, and shall set forth the best mode contemplated by the
inventor or joint inventor of carrying out the invention.”); see also MPEP § 2163, and Ariad Pharms.,
598 F.3d at 1336 (Federal Circuit has held, since 2010, that 35 U.S.C. § 112 contains both a written
description requirement and an enablement requirement, so that a patent specification must
describe the invention sufficiently for a PHOSITA to understand that the inventor possessed the
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time.136 Here, a further attempt is made to figure out how much disclosure is
enough, by elucidating the requirements for drafting a patent specification with
sufficient disclosure of the invention that supports its corresponding patent claims.137
Moreover, submission of post filing data is proposed as a limited solution in response
to a patent application being deemed as non-enabling.138
Two recent examples of non-enabling patents represent the ongoing confusion
as to what information should actually be disclosed in a patent specification in order
to enable the claimed invention.139 The way the patents are drafted emphasizes a
misguided effort to bulk up the specification with numerous embodiments describing
only some aspects of the respective claimed inventions.140 Instead, the drafters of
these patents should have made disclosures in the specifications covering each and
all of the claimed aspects of the inventions.141 This is the proper way to ensure that
the claimed inventions are supported by their respective patent specifications.142
Only after all aspects of a claimed invention are adequately disclosed in a
patent specification can post filing data apply to supplement any deficiencies or
confusion about how the invention is described during patent prosecution.143 Post
filing data does not apply when there are holes in the description of the claimed
invention such that not all aspects of the invention are addressed in the
specification.144 Drafters of patent applications should be cautious to not rely on post
filing data after the fact to fill in missing aspects of a claimed invention that the
applicant is responsible for disclosing initially at the time of filing. Nevertheless,
post filing data generated from additional experimentation after the filing of a patent
application that was done pursuant to reducing the claimed invention to practice is
acceptable to supplement the disclosure in the patent specification.145
subject matter claimed and, separately, must teach a PHOSITA how to make and use the invention.)
(A holding that has been contested up until and including Sanofi, 872 F.3d 1367.).
136 See Streck, 665 F.3d at 1269; Sitrick, 516 F.3d at 993; Liebel-Flarsheim, 481 F.3d at 1371;
Auto. Techs., 501 F.3d at 1274; AK Steel, 344 F.3d at 1234; Hoechst, 314 F.3d at 1313; Johns
Hopkins, 152 F.3d at 1342; Chugai, 927 F.2d 1200 at 1200; and Spectra-Physics, 827 F.2d at 1524.
137 See id.
138 See MPEP § 2163(I)(B).
139 See U.S. Patent Nos. 8,829,165 and 8,598,219.
140 See U.S. Patent No. 8,829,165 cols. 73–124 (Forty-one embodiments characterize the binding
possibilities between an antigen binding protein and PCSK9, but none described the actual binding
mechanism between the antibody and antigen.), and U.S. Patent No. 8,598,219 cols. 7–9 (Eight
embodiments describe different formulations of an injectable pharmaceutical drug, but none of the
examples disclosed the actual measured shelf-life of the formulations even though stability at room
temperature is claimed as an element of the invention.).
141 See MPEP § 2163(I)(A) (A claimed invention is not sufficiently disclosed in the specification if
an essential or critical aspect of the invention, claimed as an element in the patent claims, is not
adequately described and is also not conventional or known in the art by a PHOSITA.).
142 See id.
143 See MPEP § 716.09.
144 Gould, 822 F.2d at 1077–79 (Later dated submissions cannot supplement an insufficient
disclosure in a prior dated patent application to render it enabling, but they can instead be offered to
show the level of ordinary skill in the art at the time of filing of the patent application.).
145 See Brana, 51 F.3d at 1562 (Post filing data can demonstrate enablement; an inventor may
experiment after the filing date of the patent to show that the disclosure is enabling; for example,
inventors were not certain at the time of filing of their patent that their drug would be successful in
treating a specific disease, so they obtained data from clinical tests run to assess the drug’s efficacy
for treating the disease, and the post filing clinical study results were permitted to be used.).

